Industry Trends & News
-
How Diabetes Drug Distribution Just Got 10X More Complex
read more >>: How Diabetes Drug Distribution Just Got 10X More ComplexDiabetes drug distribution used to follow a relatively predictable model. Insulin dominated the biologics segment, oral drugs were handled through conventional wholesale channels, and cold chain requirements were standardized. That model no longer applies the rise of GLP-1 receptor agonists has fundamentally changed diabetes drug logistics. What was once a stable chronic disease distribution system…
-
Semaglutide vs Tirzepatide vs Retatrutide: What Pharma Distributors Need to Know Before Choosing a GLP-1 Product
read more >>: Semaglutide vs Tirzepatide vs Retatrutide: What Pharma Distributors Need to Know Before Choosing a GLP-1 ProductGLP-1 based medications are no longer just another therapeutic category. They have become one of the fastest-moving and most competitive segments in global pharmaceutical distribution. As demand for metabolic weight loss treatments continues to surge, distributors face a practical question: which GLP-1 product makes the most sense to carry, scale, and sustain? Semaglutide, tirzepatide, and…
-
HGH Market Growth Forecast: Industry Outlook Through 2030
read more >>: HGH Market Growth Forecast: Industry Outlook Through 2030The HGH Market is entering a new phase of expansion, with global demand projected to grow steadily through 2030. Driven by advancements in biotechnology, expanding clinical applications, and a rising focus on wellness and anti-aging therapies, the HGH sector—particularly somatropin—continues to attract significant investment. According to industry analysts, the global HGH market size is expected…
-
HGH Market Growth Forecast: Industry Outlook Through 2030
read more >>: HGH Market Growth Forecast: Industry Outlook Through 2030The HGH Market is entering a new phase of expansion, with global demand projected to grow steadily through 2030. Driven by advancements in biotechnology, expanding clinical applications, and a rising focus on wellness and anti-aging therapies, the HGH sector—particularly somatropin—continues to attract significant investment. According to industry analysts, the global HGH market size is expected…
-
Tirzepatide Market Size 2025: Projections, Growth Drivers, and Key Players
read more >>: Tirzepatide Market Size 2025: Projections, Growth Drivers, and Key PlayersTirzepatide market has emerged as one of the most transformative drugs in the global pharmaceutical market, redefining the treatment landscape for both type 2 diabetes and obesity. As a dual GIP and GLP-1 receptor agonist, it delivers superior efficacy in weight reduction and blood glucose management compared to earlier-generation therapies. With rapidly increasing demand, expanding…
-
GDP 2025: The Overlooked Warehouse Rule That’s Causing 80% of Audit Failures
read more >>: GDP 2025: The Overlooked Warehouse Rule That’s Causing 80% of Audit FailuresA silent crisis is unfolding in pharma logistics: 80% of recent Good Distribution Practice (GDP) audit failures trace back to one overlooked 2025 update—and most warehouses are dangerously unprepared. The culprit? EU GDP 2025’s new Chapter 9.2, which mandates:🔴 Real-time temperature monitoring (no more data loggers alone)🔴 Blockchain-based custody trails for high-risk shipments🔴 Automated deviation…
-
Global Serialization Countdown: Which Countries Are Enforcing Laws in 2025?
read more >>: Global Serialization Countdown: Which Countries Are Enforcing Laws in 2025?The world is entering the most aggressive phase of pharmaceutical serialization enforcement yet. By December 2025, 87% of global drug markets will have active serialization laws—and non-compliant companies face product seizures, steep fines, and even criminal penalties. This isn’t just about barcodes anymore. 2025 marks the tipping point where serialization becomes the universal language of…
-
FDA’s 2025 Crackdown: 5 New Rules That Could Shut Down Non-Compliant Distributors
read more >>: FDA’s 2025 Crackdown: 5 New Rules That Could Shut Down Non-Compliant DistributorsThe Coming Storm in Pharma Distribution The FDA is preparing its most aggressive regulatory overhaul in a decade, with five new rules set to take effect in 2025 that could put non-compliant distributors out of business. These changes represent a fundamental shift from voluntary guidance to mandatory enforcement – and the clock is ticking for…
-
Post-COVID Realities: 3 Distribution Models That Are Dying (And 3 Thriving)
read more >>: Post-COVID Realities: 3 Distribution Models That Are Dying (And 3 Thriving)3 Distribution Models That Are Dying, The COVID-19 pandemic permanently reshaped pharmaceutical distribution, accelerating some models to obsolescence while propelling others to new heights. As the industry adapts to post-pandemic realities, companies must rethink their distribution strategies or risk falling behind. In this article, we examine:✔ 3 outdated distribution models losing relevance✔ 3 innovative approaches…